medigraphic.com

2022, Number 2

Next >>

Rev Hematol Mex 2022; 23 (2)

Impact of positron emission tomography with fluorodeoxyglucose on the survival of patients with Hodgkin’s lymphoma in the Mexican population

Ramírez-Ibarguen AF, Nava C, García-Pérez FO, Peña-Nieves A, De la Torre-Luján A, Allende-Pérez S, Rivas-Vera S, Castillo-Llanos R, Córdova R, Pitalúa-Cortés Q

Language: English
References: 24
Page: 83-90
PDF size: 320.37 Kb.


ABSTRACT

Objetivo: To evaluate interim-positron emission tomography (PET) as a prognostic factor in terms of progression-free survival and overall survival in our population.
Materials and Methods:A retrospective, descriptive study of patients with classic Hodgkin’s lymphoma treated with the ABVD regimen (adriamycin, bleomycin, vinblastine and dacarbazine) at the National Cancer Institute in Mexico, from January 2012 to December 2015. We evaluated interim-PET, response at the end of treatment, progression-free survival, and overall survival.
Results: We analyzed 94 patients, with a median age of 34.5 years (range 16-87), 84% had advanced disease and 65% had bulky disease; complete response on interim- PET was 84%, and 78% at the end of treatment. The 5-year progression-free survival was 86% vs 7% (p = 0.0001) in patients with a negative vs a positive interim-PET, respectively. Five-year overall survival was 96% vs 76% (p = 0.0006). In multivariate analyses, interim-PET was an independent prognostic factor for progression-free survival.
Conclusions: Interim-PET was highly prognostic in patients with Hodgkin’s lymphoma and it could be more useful when adjusting treatment in our population.


REFERENCES

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classificationof Tumours of Haematopoietic and Lymphoid Tissues.Revised 4th edition. IARC: Lyon 2017.

  2. Carballo-Zarate A, Garcia-Horton A, Palma-Berre L, Ramos-Salazar P, et al. Distribution of lymphomas in Mexico: amulticenter descriptive study. J Hematopathol 2018; 11:99-105. https://doi.org/10.1007/s12308-018-0336-0.

  3. World Health Organization. Global cancer Observatory2019. Available from: https://gco.iarc.fr/today/data/factsheets/populations/484-mexico-fact-sheets.pdf.

  4. Vassilakopoulos TP, Johnson P. Treatment of advancedstage Hodgkin lymphoma: Who really needs BEACOPP?Semin Hematol 2016; 53 (3): 171-9. doi: 10.1053/j.seminhematol.2016.05.006.

  5. Diehl V, Franklin J, Pfreundschuh M. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVDfor advanced Hodgkin’s disease. N Engl J Med 2003;348: 2386-95. DOI: 10.1056/NEJMoa022473.

  6. Federico M, Luminari S, Ianitto E, Polimeno G, et al. ABVDcompared with BEACOPP compared with CEC for the initialtreatment of patients with advanced Hodgkin’s lymphoma:Results from the HD2000 Gruppo Italiano per lo Studio deiLinfomi trial. J Clin Oncol 2009; 27: 805-11. doi: 10.1200/JCO.2008.17.0910.

  7. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, et al. ABVDversus BEACOPP for Hodgkin's lymphoma when high-dosesalvage is planned. N Engl J Med 2011; 365: 203-12. doi:10.1056/NEJMoa1100340.

  8. Bröckelmann P, Angelopoulou MA, Vassilakopoulos TP.Prognostic factors in Hodgkin lymphoma. Semin Hematol2016; 53 (3): 155-64. doi: 10.1053/j.seminhematol.2016.05.003.

  9. Cheson B, Fisher R, Barrington S, et al. Recommendationsfor Initial evaluation, staging, and response assessmentof Hodgkin and non-Hodgkin lymphoma: The Luganoclassification. J Clin Oncol 2014; 32: 3059-68. doi: 10.1200/JCO.2013.54.8800.

  10. Gallamini A, Hutchings M, Rigacci L, Specht L, et al. Earlyinterim 2-[18F] fluoro-2-deoxy-D-glucose positron emissiontomography is prognostically superior to internationalprognostic score in advanced-stage Hodgkin's lymphoma:A report from a joint Italian-Danish study. J Clin Oncol 2007;25: 3746-52. doi: 10.1200/JCO.2007.11.6525.

  11. Gallamini A, Barrington SF, Biggi A, Chauvie S, et al. Thepredictive role of interim positron emission tomographyfor Hodgkin Lymphma treatment outcome is confirmedusing the interpretation criteria of Deauville five pointscale. Haematologica 2014; 99 (6): 1107-13. doi: 10.3324/haematol.2013.103218.

  12. Raemaekers JM, André MP, Federico M, Girinsky T, et al.Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associatedwith an increased risk of early relapse: Clinical results ofthe preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188-94. doi:10.1200/JCO.2013.51.9298.

  13. Johnson P, Federico M, Kirkwood A, Fossa A, et al. Adaptedtreatment guided by interim PET-CT scan in advancedHodgkin’s lymphoma. N Engl J Med 2016; 374 (25): 2419-29. DOI: 10.1056/NEJMoa1510093.

  14. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, et al. Interimpositron emission tomography response-adapted therapyin advanced-stage Hodgkin lymphoma: Final results of thephase II part of the HD0801 Study. J Clin Oncol 2016; 34(12): 1376-85. doi: 10.1200/JCO.2015.63.0699.

  15. Radford J, Illidge T, Counsell N, Hancock B, et al. Resultsof a trial of PET-directed therapy for early-stage Hodgkin’slymphoma. N Engl J Med 2015; 372: 1598-607. DOI:10.1056/NEJMoa1408648.

  16. Makita S, Maruyama D, Maeshima AM, Taniguchi H, et al.Clinical features and outcomes of 139 Japanese patientswith Hodgkin lymphoma. Int J Hematol 2016; 104 (2): 236-44. doi: 10.1007/s12185-016-2007-1.

  17. Fai-Law M, Ying Ng T, Nun Chan H, Kei Lai H, et al. Clinicalfeatures and treatment outcomes of Hodgkin’s lymphomain Hong Kong Chinese. Arch Med Sci 2014; 10 (3): 498-504.doi: 10.5114/aoms.2014.43744.

  18. Jalali A, Ha FJ, Chong G, Grigg A, et al. Hodgkin lymphoma:an Australian experience of ABVD chemotherapy inthe modern era. Ann Hematol 2016; 95 (5): 809-16. doi:10.1007/s00277-016-2611-4.

  19. Andjelic B, Antic D, Jakovic L, Todorovic M, et al. A singleinstitution experience on 314 newly diagnosed advancedHodgkin lymphoma patients: the role of ABVD in dailypractice. Eur J Haematol 2014; 93 (5): 392-9. doi: 10.1111/ejh.12364.

  20. Engert A, Haverkamp H, Kobe C, Markova J, et al. Reducedintensitychemotherapy and PET-guided radiotherapyin patients with advanced stage Hodgkin’s lymphoma(HD15 trial): a randomised, open-label, phase 3 noninferioritytrial. Lancet 2012; 379 (9828): 1791-9. doi:10.1016/S0140-6736(11)61940-5.

  21. Chisesi T, Bellei M, Luminari S, Montanini A, et al. Longtermfollow-up analysis of HD9601 trial comparing ABVDversus Stanford V versus MOPP/EBV/CAD in patients withnewly diagnosed advanced-stage Hodgkin’s lymphoma: astudy from the Intergruppo Italiano Linfomi. J Clin Oncol2011; 29 (32): 4227-33. doi: 10.1200/JCO.2010.30.9799.

  22. Skoetz N, Trelle S, Rancea M, Haverkamp H, et al. Effectof initial treatment strategy on survival of patients withadvanced-stage Hodgkin’s lymphoma: a systematic reviewand network meta-analysis. Lancet Oncol 2013; 14 (10):943-52. doi: 10.1016/S1470-2045(13)70341-3.

  23. Zaucha JM, Malkowski B, Chauvie S, Subocz E, et al. Thepredictive role of interim PET after the first chemotherapycycle and sequential evaluation of response to ABVD inHodgkin lymphoma patients - the Polish Lymphoma ResearchGroup (PLRG) Observational Study. Ann Oncol 2017;28 (12): 3051-7. doi: 10.1093/annonc/mdx524.

  24. Aldin A, Umlauff L, Estcourt LJ, Collins G, et al. InterimPET results for prognosis in adults with Hodgkin lymphoma:a systematic review and meta-analysis of prognosticfactor studies. Cochrane Database Syst Rev 2019; 9 (9):CD012643. doi: 10.1002/14651858.CD012643.pub2.




2020     |     www.medigraphic.com